8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 17, 2007)

Filed October 17, 2007For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on October 17, 2007, to announce its third-quarter 2007 financial results. The filing primarily furnished a press release detailing these results. A key aspect of the announcement is the company's use of non-GAAP financial measures, such as "net earnings excluding specified items" and "diluted earnings per common share excluding specified items." Management utilizes these non-GAAP metrics to provide investors with a clearer view of ongoing business performance by excluding unusual or unpredictable factors like merger-related costs, purchase accounting adjustments, restructuring charges, and litigation expenses. While Abbott emphasizes these measures offer valuable insights into operational effectiveness, investors are cautioned to consider them alongside, and not as a replacement for, GAAP-compliant financial figures.

Key Highlights

  • 1Abbott Laboratories announced its third-quarter 2007 financial results via an 8-K filing on October 17, 2007.
  • 2The core of the filing is the disclosure of Q3 2007 earnings and related financial information, presented in an accompanying press release (Exhibit 99.1).
  • 3Abbott employed non-GAAP financial measures in its earnings release, including net earnings and diluted EPS, excluding specified items.
  • 4These non-GAAP measures are presented to adjust for unusual or unpredictable factors such as merger costs, purchase accounting, restructuring, impairment, litigation, and regulatory changes.
  • 5The company's management believes these non-GAAP figures aid investors in better evaluating ongoing business performance.
  • 6Abbott explicitly advises investors to view these non-GAAP measures in conjunction with, and not as a substitute for, GAAP financial measures.
  • 7The filing includes Thomas C. Freyman, EVP, Finance and CFO, as the signatory, underscoring the financial nature of the report.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce Abbott Laboratories' financial results for the third quarter of 2007 and to furnish the accompanying press release that details these results.

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) calculations. Abbott uses them to present what they consider to be a clearer view of ongoing business performance by adjusting for unusual or unpredictable factors like merger costs, restructuring charges, and litigation expenses. They believe these measures help investors better evaluate the company's operational effectiveness.

No, investors should not rely solely on Abbott's non-GAAP figures. The company explicitly cautions investors to consider these non-GAAP measures in addition to, and not as a substitute for, the financial measures prepared in accordance with GAAP. GAAP figures provide the standard, audited financial picture.

Abbott's non-GAAP measures exclude items such as merger-related costs, purchase accounting adjustments, restructuring and impairment charges, certain litigation charges, and the impact of changes in laws and regulations. These are generally considered unusual or unpredictable.